Navigation Links
Avista Capital Partners Appoints Hakan Bjorklund as Healthcare Operating Executive
Date:10/6/2011

NEW YORK, Oct. 6, 2011 /PRNewswire/ -- Avista Capital Partners, a leading private equity firm, today announced that it has hired Hakan Bjorklund, the departing Chief Executive Officer of Nycomed, as Healthcare Operating Executive.  Mr. Bjorklund worked closely with Avista on the development of Nycomed during Avista's ownership of the company, which was recently sold to Takeda Pharmaceuticals Company Limited for Euro 9.6 billion.

Under Mr. Bjorklund's leadership, Nycomed was transformed from a predominantly Scandinavian business into a global pharmaceutical company with leading market positions in Europe, Russia/CIS, Brazil and Latin America.  In 2006, Mr. Bjorklund led the integration of Altana Pharmaceutical, a German-based company that Nycomed purchased for Euro 4.2 billion. He was also instrumental in growing Nycomed in emerging markets, most recently through the acquisition of Guangdong Techpool Bio-Pharma Co., Ltd, a fast growing Chinese bio-pharmaceutical company, in 2010.    

Thompson Dean, Co-Managing Partner and Chief Executive Officer of Avista, said, "We are delighted to welcome Hakan to Avista.  One of the top pharmaceutical executives in Europe, he possesses a deep understanding of the global healthcare market.  Having worked closely with him for many years, I know that Hakan will bring extensive strategic, operational and investment expertise to Avista as well as strong relationships throughout the global healthcare sector."    

Newton Aguiar, the partner in charge of Avista's European operations, added, "We are looking forward to working with Hakan on healthcare investments both in Europe and throughout the world.  Hakan built Nycomed into one of the fastest growing global pharmaceutical companies, in part, by expanding its presence in key emerging markets, particularly in Russia/CIS and Latin America.  His experience will be invaluable to the healthcare management teams in Avista's portfolio as they seek to grow their own businesses."    

Mr. Bjorklund said, "This is a very exciting opportunity. Avista is a leading private equity healthcare investor with a long track record of successful investments in the pharmaceutical, medical device, and healthcare services sectors.  As CEO of Nycomed, I was deeply impressed by the sector expertise and supportive ownership philosophy that Avista brings to its investments.  I am looking forward to helping other leading healthcare companies reach their full potential as a member of the Avista team."

Before joining Nycomed, Mr. Bjorklund was Regional Director at Astra (now AstraZeneca) and, earlier, President of Astra Draco.  He is a member of the Board of Directors of Coloplast A/S, Lundbeck A/S, and Atos Medical AB. He was also a director at Danisco A/S until its recent acquisition by Dupont.  He holds a Ph.D. in Neuroscience from Karolinska Institutet in Sweden.

In addition to Nycomed, Avista's portfolio of healthcare companies includes INC Research, a leading clinical research organization; ConvaTec, a global leader in ostomy and wound care; Lantheus, a leader in diagnostic imaging; Navilyst Medical, a manufacturer and distributor of single-use fluid management and venous-access medical devices; BioReliance, a leading contract services provider focused on biological safety testing, toxicology, viral manufacturing, and laboratory animal diagnostic services; and VWR International, a leading global distributor of equipment and consumable supplies to the laboratory sector across all industries.  In addition, during its time at DLJ Merchant Banking Partners, the Avista team was significantly involved in a variety of healthcare investments, including medical device companies such as Accellent and Kinetic Concepts; healthcare services companies such as Focus Diagnostics, Charles River Laboratories, and Fisher Scientific International; and pharmaceutical companies such as Warner Chilcott and Prometheus Laboratories.

About Avista Capital Partners

Avista Capital Partners is a leading private equity firm with offices in New York, Houston, and London. Avista's strategy is to make controlling or influential minority investments in growth-oriented energy, healthcare, media, industrial and consumer businesses. Through its team of seasoned investment professionals and industry experts, Avista seeks to partner with exceptional management teams to invest in and add value to well-positioned businesses. For more information visit www.avistacap.com.  

Contact

Melissa Sheer or James David
Kekst and Company
212-521-4825


'/>"/>
SOURCE Avista Capital Partners
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ARAMARK Agrees to Sell its Galls Business to CI Capital Partners
2. Medical Alarm Concepts Receives Growth Capital Injection and Commitment for Future Funding
3. K-V Pharmaceutical Company to Present at Imperial Capitals 5th Annual Global Opportunities Conference
4. Water Street Healthcare Partners Completes Sale and Recapitalization of CareCentrix
5. Thoratec Presentation at Lazard Capital Markets Circulatory Assist Device Day to be Webcast
6. HeartWare to Present at The Lazard Capital Markets 3rd Annual Circulatory Assist Device Day
7. HealthTech Capital Announces Two New Investments in the Emerging HealthTech Market
8. Main Street Capital Announces New Portfolio Investment
9. MGT Capital Investments, Inc.s Plan of Compliance Accepted by NYSE AMEX, LLC
10. CVS Caremark Corporation Announces Receipt of Requisite Consents, Termination of Replacement Capital Covenant and Expiration of Consent Solicitation Relating to its 6.125% Senior Notes due August 15, 2016 (CUSIP NO. 126650BE9)
11. MGT Capital Investments, Inc. Provides Update on Recent Developments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... 19, 2017 Global Prostate Cancer Therapeutics ... the prostate cancer therapeutics market analyzes the current ... prevalence of prostate cancer, launch of promising emerging ... of new drugs & therapeutic biological products, and ... to lesser side effects are some of the ...
(Date:4/19/2017)... The Global Effective Microorganisms (EM) Market by Manufacturers, ... and analysed the potential of Global Effective Microorganisms (EM) Market ... growth factors. The report identifies and analyses the emerging trends ... market. ... and Figures, 6 Major Company Profiles, spread across 124 pages ...
(Date:4/19/2017)... Companion animal vaccines ... pets such as canine, avian and feline. ... such as Attenuated Live Vaccines, Conjugate Vaccines, Inactivated ... Recombinant Vaccines. Attenuated live vaccines are derived from ... have been weakend under laboratory conditions. Conjugate vaccines ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... April 28, 2017 , ... Somnoware, a leading provider ... Online(TM), which enables sleep physicians to create and edit their interpretation reports. This ... provides a familiar interface that does not require additional training to use. It ...
(Date:4/28/2017)... NY (PRWEB) , ... April 28, 2017 , ... ... Laboratory to expanded distribution of the GlycoMark test throughout the Northeast U.S. ... hyperglycemia in patients with diabetes. The GlycoMark test provides a clinically proven one- ...
(Date:4/28/2017)... york (PRWEB) , ... April 28, 2017 , ... ... to announce that Aditya Patel M.D. has joined the revolutionary endoscopic practice under ... and board certification in Interventional Pain Medicine. The patented, revolutionary eDiscSculpt Technique created ...
(Date:4/28/2017)... ... April 28, 2017 , ... Early detection and ... drug safety and minimize the cost of development. In this webinar, sponsored by ... cell lines and for cardiac toxicity using induced pluripotent stem cells (iPSCs). , ...
(Date:4/28/2017)... ... April 28, 2017 , ... Researchers at ... ActiGraph’s CentrePoint Data Hub in a sample of participants enrolled in ... activity and sleep monitoring solutions for the global scientific community. The company’s new ...
Breaking Medicine News(10 mins):